The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79929 | SARS-CoV-2-IN-42 | SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of SARS-CoV-2 replication (EC50= 0.4 μM). | |
|
V54414 | SARS-CoV-2-IN-43 | 31356-11-3 | SARS-CoV-2-IN-43 (Compound 8h) is a potent SARS-CoV-2 replication inhibitor (antagonist) with anti-viral effect. |
|
V37542 | SARS-CoV-2-IN-44 | 1311271-71-2 | SARS-CoV-2-IN-44 is an inhibitor (blocker/antagonist) of SARS-CoV-2, with EC50 of 0.6 μM for inhibiting viral replication. |
|
V79930 | SARS-CoV-2-IN-45 | SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. | |
|
V76531 | SARS-CoV-2-IN-46 | SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor (antagonist) with EC50 of 0.9 μM in Calu-3 cells. | |
|
V78296 | SARS-CoV-2-IN-47 | SARS-CoV-2-IN-47 (Compound 13) is a SARS-CoV-2 inhibitor (IC50= 0.77 μM against Omicron BA. | |
|
V78732 | SARS-CoV-2-IN-48 | SARS-CoV-2-IN-48 (compound 19) is a SARS-CoV-2 inhibitor (antagonist) with IC50 of 2.7 μM against Omicron BA. | |
|
V78366 | SARS-CoV-2-IN-49 | SARS-CoV-2-IN-49 is an irreversible covalent binding inhibitor of the main protease of SARS-CoV-2. | |
|
V78716 | SARS-CoV-2-IN-50 | SARS-CoV-2-IN-50 (Compound X77C) is a SARS-CoV-2major protease (MPro) inhibitor. | |
|
V81367 | SARS-CoV-2-IN-51 | SARS-CoV-2-IN-51 (S-10) is a potent lead compound for Omicron fusion inhibitors. | |
|
V79291 | SARS-CoV-2-IN-53 | ARS-CoV-2-IN-53 (Compd 5d) can inhibit the replication of SARS-CoV-2 with EC50 of 14.3 μM. | |
|
V81368 | SARS-CoV-2-IN-54 | SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. | |
|
V81369 | SARS-CoV-2-IN-55 | SARS-CoV-2-IN-55 (compound 65) is a low cytotoxic SARS-CoV-2 inhibitor (antagonist) with IC50 of 0.3 μM. | |
|
V81370 | SARS-CoV-2-IN-56 | SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor. | |
|
V54428 | SARS-CoV-2-IN-57 | 1265624-68-7 | SARS-CoV-2-IN-57 (compound (+)-R-26) is a potent inhibitor of SARS-CoV-2 (IC50= 80 nM). |
|
V81371 | SARS-CoV-2-IN-58 | SARS-CoV-2-IN-58 (Compound 21H) is an antiviral compound against SARS-CoV-2 (EC50= 18 μM). | |
|
V54406 | SARS-CoV-2-IN-59 (4-(4,5-dihydro-2-imidazolyl)benzonitrile) | 850786-33-3 | SARS-CoV-2-IN-59 (compound E07) is an imidazoline analogue and a non-peptide small molecule inhibitor of SARS-CoV-2, targeting the main protease (Mpro) of coronavirus. |
|
V53063 | SARS-CoV-2-IN-6 | 2725749-22-2 | SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that displays potent enzyme inhibitory activity with IC50 of 73 nM. |
|
V81372 | SARS-CoV-2-IN-60 | SARS-CoV-2-IN-60 (compound 5a) is an S-adenosylmethionine (SAM) competitive and irreversible inhibitor of SARS-CoV-2 nsp16-nsp10 methyltransferase activity, with IC50 of 9 μM, Ki is 26 μM. | |
|
V78750 | SARS-CoV-2-IN-61 | SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor (antagonist) with IC50 of 16 µM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
